Analysed BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) News Sources
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
08-01-2026
yahoo.com
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
19-02-2026
yahoo.com
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
06-03-2026
yahoo.com
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
10-08-2026
yahoo.com
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
22-07-2026
yahoo.com
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
23-07-2026
yahoo.com
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
26-08-2026
yahoo.com
What is the current price of BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ)?
The current price of BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) is $71.97.
BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) since the previous trading day is $1.13.
BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) since the previous trading day is 1.5951%.
What is the most recent average sentiment score for BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ)?
The most recent average sentiment score for BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ)?
The most recent sentiment for BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ) is .
SEC-8K** Filing Available For BRIGHT MINDS BIOSCIENCES INC (DRUG:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.